The global menopause treatment market comprises hormonal and non-hormonal treatment products that provide relief from symptoms arising during menopause such as hot flashes, night sweats, and mood swings among others. Hormonal treatment products including estrogen and progesterone drugs are prescribed to replenish hormone levels in women during this phase. Non-hormonal treatment includes dietary supplements, herbal medicines, and prescription drugs that help alleviate menopause symptoms without introducing hormones. The need for effective menopausal treatment options is rising with increasing awareness about available treatment alternatives among women worldwide.
The global menopause treatment market was valued US$ 15.33 Bn in 2023 and is expected to reach US$ 24.33 Bn by 2031 growing at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.
Key Takeaways
Key players operating in the global menopause treatment are Novartis AG, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Novo Nordisk A/S, illendo Therapeutics, Inc., Mithra Pharmaceuticals,Merck and Co., Inc, Cipla Inc., Abbott, Viatris Inc., Organon, SnapNurse, Glenmark Pharmaceuticals Limited, Procter and Gamble, Duchesnay USA.,TherapeuticsMD, Inc., Amneal Pharmaceuticals LLC. These players dominate the market with their extensive hormonal and non-hormonal treatment portfolios.
The Global Menopause Treatment Market Growth is growing due to increasing awareness about available treatment alternatives among women. As women become more aware of menopause symptoms and options to alleviate them, the adoption of prescribed and over-the-counter treatment products is rising.
Get More Insights on- Global Menopause Treatment Market
